1062822--3/12/2007--LEXICON_GENETICS

related topics

{product, candidate, development}

{property, intellectual, protect}

{cost, regulation, environmental}

{stock, price, operating}

{product, liability, claim}

Our operating results have been and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance. Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval. Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts. We face substantial competition in our drug discovery and product development efforts. We use hazardous chemicals and radioactive and biological materials in our business; any disputes relating to improper handling, storage or disposal of these materials could be time consuming and costly. We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our discovery and development and planned commercialization activities. We may not prevail in any such litigation or other dispute or be able to obtain required licenses. Our industry is subject to extensive and uncertain government regulatory requirements, which could significantly hinder our ability, or the ability of our collaborators, to obtain, in a timely manner or at all, regulatory approval of potential therapeutic products, or to commercialize such products. We may be sued for product liability.

Full 10-K form ▸

1062822--3/12/2007--LEXICON_GENETICS_INC/TX